Abstract
Background: The most common malignancy of females of Egypt is breast cancer. It accounts for 32 per cent of women's cancer. Clarifying and assessing prognostic factors associated with breast cancer is essential as they are the corner stone to identify the high-risk groups that can benefit from adjuvant therapy and improve their prognosis for the disease. Study Objective: The aim of this study was to assess the role of serum omentin-1 levels in the Egyptian female population as prognostic markers for breast cancer. Patients and methods: Study subjects are 120 BC patients and 30 age and BMI matching health controls, serum omentin-1 levels have been investigated and correlated with the clinicopathological aspects of the BC patients Results : Our study revealed a significant difference in omentin-1 between healthy controls and BC patients, and a gradual increase in severity of the disease. Conclusion: our findings suggested that omentin-1 could be a diagnostic marker for early detection of cases and associated with the prognosis of breast cancer, supporting its role as biomarkers of the prognosis.
Highlights
Breast cancer is a disease well characterized by etiological and pathological heterogeneity, it shows extreme variability in the course and prognosis of affected patients
The sensitivity and specificity of which were 82% and 78% respectively. This is comparable with the result found by Tahmasebpour et al, who found that the reliable cutoff value differentiating healthy subjects from breast cancer patients was 136.5ng/L, with concluded sensitivity and specificity of 63.64% and 89.02% respectively [17]
The results of Nourbakhsh et al was in concordance with our results as the found that omentin-1 levels may be beneficial in the diagnosis and prognosis of invasive breast carcinoma [18]
Summary
Breast cancer is a disease well characterized by etiological and pathological heterogeneity, it shows extreme variability in the course and prognosis of affected patients. In the National Cancer Institute-Cairo University (NCI-CU), breast cancer cases are representing 19.3% of total primary malignancies [2]. These data is giving indicators about the extent of the disease as well as its morbidity and mortality magnitude, eliciting the urgent need for proper management protocols [3]. The potential uses of serum markers in breast cancer include aiding early diagnosis, determining prognosis, prospectively predicting response or resistance to specific therapies, surveillance after primary surgery, and monitoring therapy in patients with advanced disease. The aim of this review is to examine the role of serum tumor markers in the detection and management of patients with breast cancer [4]. A number is added to each letter to indicate the size and/or extent of the primary tumor and the degree of cancer spread [5]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
